Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025
Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, has scheduled its Q1 2025 financial results announcement for Thursday, May 8, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results.
Participants must pre-register for the conference call through a provided link. A live webcast will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.
Lisata Therapeutics (NASDAQ: LSTA), un'azienda farmaceutica in fase clinica focalizzata sullo sviluppo di terapie per tumori solidi avanzati e altre malattie gravi, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call alle 16:30 ora della costa orientale per discutere i risultati.
I partecipanti devono registrarsi in anticipo per la conference call tramite un link fornito. Una diretta web sarà disponibile sul sito di Lisata nella sezione Investitori & Notizie, con una registrazione accessibile per 12 mesi dopo la chiamata.
Lisata Therapeutics (NASDAQ: LSTA), una empresa farmacéutica en etapa clínica enfocada en desarrollar terapias para tumores sólidos avanzados y otras enfermedades graves, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, después del cierre del mercado. La compañía realizará una llamada de conferencia a las 4:30 p.m. hora del este para discutir los resultados.
Los participantes deben preinscribirse para la llamada a través de un enlace proporcionado. Habrá una transmisión en vivo disponible en el sitio web de Lisata en la sección de Inversores y Noticias, con una repetición accesible durante 12 meses después de la llamada.
Lisata Therapeutics (NASDAQ: LSTA)는 진행성 고형암 및 기타 중증 질환 치료제 개발에 주력하는 임상 단계 제약회사로, 2025년 5월 8일 목요일 장 마감 후 2025년 1분기 재무실적 발표를 예정하고 있습니다. 회사는 동부 표준시 오후 4시 30분에 실적 관련 컨퍼런스 콜을 진행할 예정입니다.
참석자는 제공된 링크를 통해 사전 등록해야 하며, 라이브 웹캐스트는 Lisata 웹사이트의 투자자 및 뉴스 섹션에서 시청할 수 있습니다. 컨퍼런스 콜 후 12개월 동안 다시보기 서비스도 제공됩니다.
Lisata Therapeutics (NASDAQ : LSTA), une société pharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les tumeurs solides avancées et d'autres maladies graves, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025, après la clôture des marchés. La société organisera une conférence téléphonique à 16h30 heure de l'Est pour discuter des résultats.
Les participants doivent s'inscrire à l'avance via un lien fourni. Un webcast en direct sera disponible sur le site de Lisata dans la section Investisseurs & Actualités, avec une rediffusion accessible pendant 12 mois après la conférence.
Lisata Therapeutics (NASDAQ: LSTA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für fortgeschrittene solide Tumoren und andere schwere Erkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, nach Börsenschluss geplant. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
Teilnehmer müssen sich über einen bereitgestellten Link für die Telefonkonferenz vorab registrieren. Ein Live-Webcast wird auf der Website von Lisata unter der Rubrik Investoren & Nachrichten verfügbar sein, mit einer Wiedergabe, die 12 Monate nach dem Anruf abrufbar ist.
- None.
- None.
BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into the second quarter of 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Account Supervisor
Phone: 203-682-4783
Email: elizabeth.coleman@icrhealthcare.com
FAQ
When will Lisata Therapeutics (LSTA) report Q1 2025 earnings?
What time is Lisata Therapeutics' (LSTA) Q1 2025 earnings call?
How can I access Lisata Therapeutics' (LSTA) Q1 2025 earnings call?
How long will Lisata Therapeutics' (LSTA) Q1 2025 earnings call replay be available?
